Epigenetic drug 5-azacytidine impairs proliferation of rat limb buds in an organotypic model-system in vitro

Aim To establish an organotypic in vitro model of limb bud development to verify whether epigenetic drug and teratogen 5-azacytidine (5azaC) has an effect on limb buds independent of its effects on the placenta.

Methods Fischer strain rat fore- and hindlimb buds were microsurgically isolated from 13 days old embryos and cultivated in vitro for two weeks at the air-liquid interface in Eagle’s minimum essential medium (MEM) with 50% rat serum. 30 µmol of 5azaC was added to the fresh medium. Overall growth was measured by an ocular micrometer. Routine histology, immunohistochemical detection of the proliferating cell nuclear antigen (PCNA), and stereological quantification of PCNA expression were performed.

Results At four time points, significantly lower overall growth was detected for fore- and hindlimb bud explants cultivated with 5azaC in comparison to controls. After the culture period, numerical density of the PCNA signal for both types of limb buds was lower than for controls (P < 0.001). Limb buds were initially covered by immature epithelium and contained mesenchyme, myotubes, single hemangioblasts, hemangioblast aggregates, blood islands, and capillaries. Regardless of the treatment, cartilage and epidermis differentiated, but cells and structures typical for vasculogenesis disappeared.

Conclusion Our findings, obtained outside of the maternal organism, stress the importance of compromised cell proliferation for 5azaC impact on limb buds. This investigation points to the necessity to establish alternatives to in vivo research on animals using teratogenic agents.
Epigenetics deals with heritable changes in gene expression or cellular phenotype. They are caused mainly by changes in DNA methylation and histone code without changes in the underlying DNA sequence. Epigenetic research has especially been focused on development (1) and cancer (2,3). This research led to an entirely new class of so-called epigenetic drugs, which have recently entered clinical trials (4). Possible side-effects and teratogenicity caused by these drugs are of substantial importance for human medicine.

One of the archetypal epigenetic therapeutic agents, the DNA demethylating agent 5-azacytidine (5azaC) has been approved by US Food and Drug Administration for treatment of myelodysplastic syndrome in all its subtypes (5). Although the rationale for its approval was its ability to demethylate and activate genes such as tumor suppressors, only recently its genome-wide activity has been addressed (6) and it has been found out that it is also able to reorganize histone modification patterns (7). Because it changes gene expression necessary for the normal course of development, 5azaC has been known to influence developmental parameters such as survival, differentiation, growth, and morphogenesis. Applied in vivo during rat gestation, it was embryotoxic or caused malformations in a stage-specific manner. Until the 11th day, embryos were susceptible to resorptions, while later overall growth (weight and crown-rump length) was impaired. The most critical period for induction of limb malformations was from the 12th to 13th day (8). Because 5azaC also impaired placental growth and morphology, the question remains whether it is directly affecting limb buds or acting indirectly by affecting placental function (9,10).

It is possible to investigate the influence of 5-azaC on the embryo in a specific in vitro model of rat embryonic development at the air-liquid interface, without the confounding change in the placenta (11,12). When applied in serum-free conditions to the gastrulating rat embryo (consisting of epiblast and hypoblast), 5azaC impaired survival, growth, and differentiation (11) but in serum-supplemented conditions it promoted differentiation of muscle (12). In a culture of a younger, pre-gastrulating embryo (consisting of epiblast and hypoblast), it promoted differentiation of muscle, cartilage, blood islands, and neural tissue (13). Recent results associate the impact of 5azaC in an in vitro cell culture developmental model with a decrease in cell proliferation (14). On the other hand, in a cartilaginous organ transplanted in vivo it enhanced cell proliferation (15). This may seem to be controversial but 5azaC acted specifically for each developmental model system.

According to the original organ-culture model at the air-liquid interface established before for investigation of developmental processes in the rat embryo (12), we aimed to establish a new in vitro organotypic model-system for rat limb bud development. In this model, the overall growth of explanted limb buds could be assessed at several points during the culture period and, at the end of culture, the ability for cell proliferation at the single cell level could be assessed by a cell proliferation marker. The proliferating cell nuclear antigen (PCNA) expression was stereologically quantified similarly as in our in vivo experiments (10). Establishing such an in vitro experimental model, in which the influence of 5azaC on maternal organism is avoided, a clear answer could be obtained about the susceptibility of limb buds to 5azaC. Moreover, it would be possible to resolve the dilemma about 5azaC impact on cell proliferation in the developing limb bud as a whole organ.

MATERIAL AND METHODS

Isolation of rat limb buds

Fischer strain rats were mated overnight and the finding of sperm in the vaginal smear next morning designated the day 0 of pregnancy. Females were euthanized with anesthetic and 13 days old fetuses were isolated. A total of 128 fore- and hindlimb buds were microsurgically isolated under the dissecting microscope by Graeffe’s knife and a watchmaker’s forceps and rinsed in phosphate buffered saline (PBS). The experiments were approved by the Ethics Committee of University of Zagreb School of Medicine.

Organ culture in vitro

Isolated limb buds (N = 32 per group) were grown in disposable organ culture dishes with a central well (Falcon No 3037, Becton Dickinson, Oxford, UK) on stainless steel grids made at the Department of Medical Biology, University of Zagreb School of Medicine, and covered with a piece of lens paper (Whatman Grade 105, Sigma Aldrich, Taufkirchen, Germany). Eagle’s minimal essential medium (MEM) with Hanks’ salt solution (Sigma Aldrich) with 50% rat serum was poured under the grid to wet the paper. Rat serum was obtained from aortal bifurcation of anesthetized male rats and immediately inactivated at 56°C. 30 µM 5azaC (Sigma Aldrich) in MEM and 50% rat serum was used for cultivation of experimental samples. Limb buds were
grown in an incubator at the air-liquid interface for two weeks in 5% CO₂ and 95% air at 37°C. The culture medium was changed five times during the culture period.

**Overall growth of explants**

To monitor growth, ellipsoid explants major and minor diameters were measured by an ocular micrometer at the beginning of the culture period and four times at the time of the culture medium change (16,17). Measures were included in the formula for ellipse area \( A = \pi \times \text{major diameter} \times \text{minor diameter} / 4 \). Calculated \( A \) values (ranging from 2.4 to 2.6 mm²) were normalized by division to values of the initial measurement and used as the measure of overall growth \( A/A_0 \). Therefore, \( A/A_0 \) was 1 for the day 0 when the explants were plated at the air-liquid surface.

**Histology and immunohistochemistry**

Explants were fixed by St. Marie solution (1% acetic acid in 96% ethanol, +4°C), embedded in paraffin and 5 μm histological sections were prepared. Some samples were processed for routine histology and stained with hematoxylin-eosin (HE) or Masson trichrome stain. For immunohistochemistry, sections (5 μm) were put on silanized slides (DAKO, Glostrup, Denmark) and air-dried for 24 hours at room temperature. Sections were deparaffinized in xylene (2 × 5 minutes), treated with absolute ethanol and 96% ethanol (2 × 5 min), 70% ethanol, and PBS (5 minutes). Epitope retrieval was done in the Target Retrieval Solution (DAKO ChemMateTM) (×10) in a microwave oven according to the manufacturer’s instructions. Monoclonal mouse PCNA, Clone PC 10 (DAKO), was diluted to 1:100 and applied overnight. Negative controls were treated with an unspecific antibody (No. V 1617 mouse IgG, DAKO). Labeled streptavidin–biotin kit (Dakocytomation, LSAB®2 System–HRP, DAKO), Streptavidin/HRP (DAKO), and chromogen system (Dakocytomation, Liquid DAB+ substrate, DAKO) was used according to manufacturer’s instructions. Sections were briefly counterstained with hematoxylin, washed with distilled water, then for 20 minutes in tap water, again for 3 minutes in distilled water, and covered with 50% glycerol in PBS.

**Stereology**

Cells positive for PCNA were stained by DAB (brown). The signal was always present in the nuclei although the cytoplasmic signal together with the conspicuous nuclear staining was also found. Nuclei of the cells that were negative for PCNA were stained by the counterstain (blue) (9,10,15). Randomly selected paraffin blocks (6 for each group of explants – total 24 blocks) were used for stereological analysis of PCNA-positive cells. Five consecutive sections were taken randomly from each block and quantitative stereological analysis of numerical density \( (N_v) \) was performed by Nikon Alphaphot binocular light microscope (Nikon, Vienna, Austria) using Weibel’s multipurpose test system with 42 points (M 42) at a magnification of 400 ×. The area tested \( (A) \) was 0.0837 mm². For each investigated group the orientation/pilot stereological measurement was carried out on 10 fields in order to define the number of fields to be tested. The results were included in the formula \( n = (200/y \times s/\text{arithmetic mean})^2 \) (18), where \( n \) is the number of fields to be analyzed, the arithmetic mean is of the orientation sample, \( s \) is standard deviation, and \( y \) the allowed deviation from the arithmetic mean at the 95% confidence interval, which reflects the significance level of 0.05. At least 15 fields per group were analyzed. The numerical density of PCNA-positive cells was determined by the point counting method. Numerical density \( (N_v) \) was calculated by the formula \( N_v = N/A \times D \), where \( N \) is the number of PCNA-positive cells in the tested area. The mean tangential diameter \( (D) \) was calculated by Ellipse 3D program and for 100 cells it was 0.0147 mm and the test-area \( (A) \) was 0.0837 mm². Results were analyzed by t test and the statistical significance level was \( P<0.05 \).

**RESULTS**

**Overall growth**

Throughout the culture period, overall growth of explants was lower in 5azaC treated explants. For the forelimb buds, a significant difference between experimental and control groups was first discovered at the fourth day of the culture, and for the hindlimb buds a significant difference was first discovered at the sixth day (Table 1).

**Proliferating cell nuclear antigen expression**

The expression of the proliferating cell nuclear antigen, a marker of proliferating cells, was found in all explants regardless of the culture conditions but not in all cells (Figure 1A). Numerical density \( (N_v) \) of PCNA signals was significantly lower for explants treated with 5azaC (Table 1).

**Differentiation**

Native 13 days old limb buds explanted from the rat embryo contained a central mass of mesenchyme cov-
ered with immature epithelium (Figure 1B, C, D). Within the mesenchyme myotubes (Figure 1E) and various stages of vasculogenesis, such as single hemangioblasts, their aggregates, blood islands and capillaries were found (Figure 1F, G).

Explants survived for two weeks in vitro at the air-liquid interface. In those limb buds, keratinized epidermis differentiated and it contained all five layers, among which there was a prominent stratum granulosum, typical for the thick skin (Figure 1H). Cartilage enveloped in perichondrium differentiated (Figure 1I). Peripheral areas typical for apposition growth and centrally positioned areas typical for interstitial growth were present within the cartilage. Interstitial growth was recognized by the presence of several chondrocytes in a single lacuna (isogenic group). The lacunae were surrounded by the extracellular matrix. While myotubes were still occasionally found, cells and structures typical for vasculogenesis were absent from the explants after the cultivation period in vitro (Figure 1H, I). Careful histological examination revealed no difference regarding differentiation between explants grown in control conditions and those grown in experimental conditions with 5azaC.

**DISCUSSION**

By using a novel approach in which limb buds were subjected to 5azaC outside of the maternal organism, we analyzed its impact on the limb bud development. For the first time it was shown that it impaired both overall growth and ability for cell proliferation in the whole developing limb bud. In such a system, tissue interactions needed for the limb bud development are partially preserved, which makes this system more similar to in vivo situation than simple cell cultures and therefore more suitable as an alternative to in vivo research (11).

Negative influence upon overall growth took place earlier for the forelimbs than for the hindlimbs, possibly because mammalian fore limbs develop earlier than hind limbs (19).

The marker of cell proliferation which was used (PCNA) is a ring protein that functions as a sliding clamp necessary as an essential cofactor for DNA synthesis (20). Although its immunohistochemistry levels in rat renewing tissues were found to be higher than those of other cell proliferation markers, those markers sometimes could not be visualized due to technical problems (21). In our current experiments, in the same way as in previously published studies (9,10,15), PCNA signal was always easily detected. The quantitative difference in its expression (Nv), found between experimental and control groups of limb buds, was in accordance with the results obtained by measurements of the overall explant growth.

| TABLE 1. Decrease in overall growth and the proliferating cell nuclear antigen (PCNA) expression in rat limb buds cultivated with 5azaC |
|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| Forelimb buds           | Controls                | 5azaC                   | t           | P          |
| Overall growth          | No. of samples | A/A₀ * (mean±SE)² | No. of samples | A/A₀ (mean±SE)² | t          | P          |
| Day 4                   | 19                     | 1.194±0.050            | 17           | 0.972±0.050 | 3.112      | 0.004      |
| Day 6                   | 16                     | 1.155±0.041            | 17           | 0.882±0.034 | 5.151      | <0.001     |
| Day 8                   | 14                     | 1.015±0.057            | 17           | 0.795±0.040 | 3.251      | 0.003      |
| Day 11                  | 8                      | 1.214±0.082            | 17           | 0.7559±0.051| 4.915      | <0.001     |
| PCNA expression         | No. of samples/ microscopic fields | Nv of PCNA in mm⁻³ (mean±SE) | No. of samples/ microscopic fields | Nv of PCNA in mm⁻³ (mean±SE) | t          | P          |
| Day 14                  | 6/15              | 65755±1672             | 6/42         | 50824±2325 | 4.770      | <0.001     |
| Hindlimb buds           | No. of samples | A/A₀ (mean±SE)² | No. of samples | A/A₀ (mean±SE)² | t          | P          |
| Day 4                   | 18                     | 1.066±0.055            | 31           | 1.137±0.040 | 1.055      | 0.297      |
| Day 6                   | 17                     | 1.164±0.077            | 19           | 0.864±0.028 | 3.813      | 0.001      |
| Day 8                   | 17                     | 1.041±0.070            | 19           | 0.740±0.043 | 3.762      | 0.001      |
| Day 11                  | 17                     | 1.089±0.075            | 19           | 0.666±0.028 | 5.522      | <0.001     |
| PCNA expression         | No. of samples/ microscopic fields | Nv of PCNA in mm⁻³ (mean±SE) | No. of samples/ microscopic fields | Nv of PCNA in mm⁻³ (mean±SE) | t          | P          |
| Day 14                  | 6/33                   | 64580±2124             | 6/31         | 45042±1726 | 7.000      | <0.001     |

* A/A₀ – explant area/explant area at the beginning of culture.  
**SE – standard error of the mean.**
found as a result of 5azaC application during gestation are predominantly caused by its antiproliferative activity such as shown in our study. Interestingly, the rationale underlying the low dose therapy with the DNA demethylating agent currently approved for myelodysplastic syndrome is based on the theory that induction of hypomethylation with subsequent re-expression of methylated genes will induce gene expression patterns and beneficially result in differentiation, apoptosis, or senescence of the malignant clone (23). In addition, a decrease in cell growth with an arrest of the cell cycle at G0/G1 phase seems to precede such events (24).

In our system, differentiation of isolated limb buds proceeded. By carefully performed light microscopy, advanced differentiation of cartilage and epidermis was discovered after a two-week culture with no difference found between explants treated or untreated with 5azaC. However, during in vitro culture, vasculogenesis found in 13 days old isolated limb buds seems to have disappeared. The reason for this was probably the lack of specific in vivo signals, which are absent from the simple in vitro environment (15).

The in vitro rat developmental model used in this investigation is in accordance with the need to find alternatives to in vivo developmental toxicity studies because of ethical and economical constrains. This includes search for novel in vitro biomarkers. Although two rat assays have already been validated by the European Centre for the Validation of Alternative Methods, they deal with limb buds either

![Figure 1](image-url)
dissociated (micromass test) or developed after two days in the whole rat embryos (WEC) isolated at GD10. In the micromass test, a strong embryotoxic compound was classified as nonembryotoxic and WEC was found to be predictive only in combination with a 3T3 cell assay (25-27). These models are different from our organotypic model, which enables investigation of substance impact for the prolonged period of two weeks in an organ that is achieving a high degree of differentiation, higher than in WEC. Therefore, our rat limb bud model-system with quantitative endpoints defined in this investigation (overall growth and cell proliferation) might be proposed as a complementary model, which may provide more information about developmental toxicity during organogenesis.

To conclude, by the novel in vitro approach we eliminated maternal and placental effect and gave a more straightforward answer about the negative impact of 5azaC on limb bud development. The results of this investigation stress the impact of decreased proliferation for 5azaC teratogenicity.

Funding This research was supported by grant No. 108-1080399-0335, Experimental Embryonic Tumors and Development of the Mammalian Embryo In Vitro and No. 108-1080399-0383, In Vivo and Male and Female Reproductive Organs: Development, Normal Histophysiology and Infertility within the program Biomedical Investigation of Mammalian Reproduction and Development from the Ministry of Science, Education, and Sports of the Republic of Croatia.

Ethical approval received from the Ethical Committee, University of Zagreb School of Medicine.

Declaration of authorship VM made the initial proposal for the study, coordinated the research, participated in data analysis and interpretation and writing of the manuscript. AKB performed statistical analysis, immunohistochemistry protocols, and interpretation of data. NM performed histological analysis and interpretation of data. KT performed experiments with laboratory techniques and data analysis. NM performed in vitro culture and data analysis, LJ performed stereological analysis and data interpretation, NS provided advice on the experimental analysis and took part in manuscript preparation, MV performed interpretation of results and writing of the manuscript; FB-J devised the method and protocols used for in vitro analyses, approved the study design and scope, and helped the lead author in writing of the manuscript.

Competing interests All authors have completed the Unified Competing Interest form at www.cmj.hr/ethics_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Kiefer JC. Epigenetics in development. Dev Dyn. 2007;236:1144-56. Medline:17304537 doi:10.1002/dvdy.21094
2 Sincic N, Herceg Z. DNA methylation and cancer: ghosts and angels above the genes. Curr Opin Oncol. 2011;23:69-76. Medline:21119515 doi:10.1097/GOO.0b013e3283412eb4
3 Herceg Z. Epigenetic information in chromatin and cancer. Eur J Cancer. 2009;45 Suppl 1:442-4. Medline:19775664 doi:10.1016/S0959-8049(09)70082-6
4 Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-9. Medline:21386836 doi:10.1038/nm.2305
5 Raj K, Mufti GJ. Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2006;2:377-88. Medline:18360650 doi:10.2147/tcrm.2006.2.4.377
6 Hagman S, Raunio M, Rossi M, Dastidar P, Elovaara I. Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: prospective clinical and MRI follow-up study. J Neuroimmunol. 2011;234:141-7. Medline:21397339 doi:10.1016/j.jneuroim.2011.02.009
7 Komaskho VM, Farnham PJ. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics. 2010;5. Medline:20305384 doi:10.4161/epi.5.3.11409
8 Sincic N, Vlahovic M, Bulic-Jakus F, Serman D, Serman D. Acetylsalicylic acid protects rat embryos from teratogenic effects of 5-azacytidine. Period Biol. 2002;104:441-4.
9 Vlahovic M, Bulic-Jakus F, Juric-Lekic G, Fucic A, Maric S, Serman D. Changes in the placenta and in the rat embryo caused by the demethylation agent 5-azacytidine. Int J Dev Biol. 1999;43:843-6. Medline:10707910
10 Serman L, Vlahovic M, Sijan M, Bulic-Jakus F, Serman A, Sincic N, et al. The impact of 5-azacytidine on placental weight, glycophorin pattern and proliferating cell nuclear antigen expression in rat placenta. Placenta. 2007;28:803-11. Medline:17509679 doi:10.1016/j.placenta.2007.04.001
11 Bulic-Jakus F, Vlahovic M, Juric-Lekic G, Crnek-Kunstelj V, Serman D. Gastrulating rat embryo in a serum-free culture model: Changes of development caused by teratogen 5-azacytidine. Atla-Alternatives to Laboratory Animals. 1999;27:925-33.
12 Skreb N, Bulic-Jakus F, Crnek V, Stepic J, Vlahovic M. Differentiation and growth of rat egg-cylinders cultured in vitro in a serum-free and protein-free medium. Int J Dev Biol. 1993;37:151-4. Medline:7685183
13 Vlahovic M, Bulic-Jakus F, Juric-Lekic G, Crnek-Kunstelj V, Serman D. Gastrulating rat embryo in a serum-free culture model: Changes of development caused by teratogen 5-azacytidine. Atla-Alternatives to Laboratory Animals. 1999;27:925-33.
14 Montesano A, Luizi L, Senesi P, Terruzzi I. Modulation of cell cycle progression by 5-azacytidine is associated with early myogenesis induction in murine myoblasts. Int J Biol Sci. 2013;9:391-402. Medline:23678289 doi:10.7150/ijbs.4729
15 Marinovic-Kulisic S, Juric-Lekic G, Vikic-Topic M, Lokosek V, Radukjovic V, Bulic-Jakus F, et al. 5-azacytidine enhances proliferation in transplanted rat fetal epiglottis. Front Biosci (Elite Ed). 2011;3:581-90. Medline:21196336 doi:10.2741/e271
16 Skreb N, Crnek V. Development of embryo-derived teratomas in...
vitro. In: McKinnel RG, Di Berardino MA, Blumenfeld M, Bergad RD, editors. Differentiation and Neoplasia. Berlin: Springer-Verlag; 1980. p. 283-9.

17 Škreb N, Bulić F. Partial differentiation of rat egg cylinders in serum-free and protein-free medium. Dev Biol. 1987;120:584-6. Medline:3556768 doi:10.1016/0012-1606(87)90261-2

18 Kališnik M. Basics of stereology [in Croatian]. Acta stereol. 1985;4:1-148.

19 Vlahovic M, Sincic N, Bulić-Jakus F, Serman L, Serman D. Acetylsalicylic acid seems to diminish teratogenic effects of 5-azacytidine. Period Biol. 2001;103:343-6.

20 Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007;129:665-79. Medline:17512402 doi:10.1016/j.cell.2007.03.003

21 Muskhelishvili L, Latendresse JR, Kodell RL, Henderson EB. Evaluation of cell proliferation in rat tissues with BrdU, PCNA, Ki-67 (MIB-1) immunohistochemistry and in situ hybridization for histone mRNA. J Histochem Cytochem. 2003;51:1681-8. Medline:14623936 doi:10.1177/002215540305101212

22 Zeller R, Lopez-Rios J, Zuniga A. Vertebrate limb bud development: moving towards integrative analysis of organogenesis. Nat Rev Genet. 2009;10:845-58. Medline:19920852 doi:10.1038/nrg2681

23 Griffiths EA, Gore SD. DNA methyltransferase inhibitors: class effect or unique agents? Leuk Lymphoma. 2008;49:650-1. Medline:18398728 doi:10.1080/10428190801947575

24 Poirier F, Bourin P, Bladier D, Joubert-Caron R, Caron M. Effect of 5-azacytidine and galectin-1 on growth and differentiation of the human b lymphoma cell line bl36. Cancer Cell Int. 2001;1:2. Medline:11983026 doi:10.1186/1475-2867-1-2

25 Jochem J, Kalarus Z, Spaccapelo L, Canalini F, Ottani A, Giuliani D, et al. Centrally acting leptin induces a resuscitating effect in haemorrhagic shock in rats. Regul Pept. 2012;176:45-50. Medline:22465165 doi:10.1016/j.regpep.2012.03.003

26 Robinson JF, Verhoeef A, Piersma AH. Transcriptomic analysis of neurulation and early organogenesis in rat embryos: an in vivo and ex vivo comparison. Toxicol Sci. 2012;126:255-66. Medline:22262562 doi:10.1093/toxsci/kfr343

27 Piersma AH. Validation of alternative methods for developmental toxicity testing. Toxicol Lett. 2004;149:147-53. Medline:15093260 doi:10.1016/j.toxlet.2003.12.029